In schizophrenia, cognitive dysfunction is highly predictive of poor patient outcomes and is not responsive to current medications. Postmortem studies have suggested that cognitive deficits in schizophrenia are correlated with modifications in the number and size of inhibitory synapses. To test if these modifications lead to cognitive deficits, we have created a dominant-negative virus [adeno-associated (AAV)-DN1] that disrupts the clustering of γ-aminobutyric acid type A receptors (GABA A Rs) at postsynaptic inhibitory specializations. When injected into the frontal cortex of mice, AAV-DN1 impairs GABA A R α2 subunit and GABA transporter 1 (GAT-1) clustering, but increases GABA A R α1 subunit clustering on the perisomatic region, with no influence on axon-initial segment clustering. Mice expressing AAV-DN1 have prepulse inhibition deficits and impairments in working memory. Significantly, these behavioral deficits are paralleled by a reduction in electroencephalography γ-power. Collectively, our study provides functional evidence revealing that GABAergic synapses in the prefrontal cortex directly contribute to cognition and γ-power.
I
n schizophrenia, the classical positive and negative symptoms are accompanied by striking cognitive deficits, and notably, the cognitive deficits are not ameliorated by conventional antipsychotic medications (1) (2) (3) . Thus, understanding the molecular basis of these deficits is key to development of more efficacious treatments. In addition to modifications in the dopaminergic system, there is compelling evidence that modifications in signaling by γ-aminobutyric acid receptors (GABA A R) contributes to the cognitive deficits in schizophrenia. GABA A Rs are the principle mediators of fast synaptic inhibition in the brain and are pentameric heteroligomers that are principally assembled from α1-6, β1-3, γ1-3, and δ subunits (4) . Within the cortex, GABA A Rs containing α2 subunits are enriched on the axoninitial segments (AIS) and perisomatic regions of neurons, where their activation has been shown to underlie oscillatory activity and cognition (5, 6) .
Postmortem analysis has revealed increased levels of α2 subunit immunoreactivity on the AIS of principal cortical neurons in schizophrenia and parallel deficits in the number of GABA transporter (GAT-1) positive presynaptic elements. However, whether these modifications in inhibitory synapse structure contribute to the cognitive deficits of schizophrenia remains unknown. To address this issue we have used virally encoded dominantnegative reagents to disrupt the function of inhibitory synapses containing α2 subunits in the cortex of mice. This resulted in prepulse inhibition deficits and impairments in working memory that were paralleled by a reduction in electroencephalography γ-power. Thus, α2 subunit-containing GABA A Rs are important determinants of cognition, and selectively potentiating their activity may be beneficial in improving the outcome of patients with schizophrenia.
Results

Creation of Dominant Negative Reagents to Disrupt the Synaptic
Accumulation of GABA A Rs. The stabilization of GABA A Rs at inhibitory synapses is dependent upon the direct binding of residues 360-375 within the intracellular domains of α1 and α2 subunits to the inhibitory scaffold protein gephyrin (7) (8) (9) . To disrupt the accumulation of GABA A Rs at inhibitory synapses we used a fusion protein based on the intracellular domain of the α1 subunit in which residues 360-375 were replaced by those from the α2 subunit fused to transmembrane (M) domains 3 and 4 of the α1 subunit (8) . M3 was then fused to the extracellular domain of CD4 modified at its N terminus with GFP to create CD4DN1 (Fig. 1A) . We began by analyzing the effects of this construct (or a control in which CD4 was directly fused to GFP) on the properties of miniature inhibitory synaptic currents; the data for these studies are summarized in SI Appendix, Table S1 . CD4DN1 significantly decreased mIPSC amplitude compared with CD4GFP (P = 0.03; SI Appendix, Fig. S1 A and B) and induced a leftward shift in the cumulative miniature Inhibitory Postsynaptic Current (mIPSC) amplitude with a significant reduction in median amplitude (P < 0.001; SI Appendix, Fig. S1C ). The decay times for mIPSCs in neurons expressing CD4DN1 were significantly faster than for neurons expressing CD4GFP, whereas rise times remained Significance Schizophrenia is a condition characterized by interrelated symptoms including psychosis and hallucinations, decreased emotional expression and motivation, and cognitive impairments. Recent studies have shown that γ-aminobutyric acid (GABA), the principal inhibitory neurotransmitter in the brain, contributes to the cognitive symptoms of schizophrenia. However, the details of this alteration are not understood. GABA signaling can exert powerful control on groups of neurons, acting as regulated onoff switches for brain activity. In the brains of patients with schizophrenia, an alteration in the typical on-off patterns is observed. We generated an animal model for symptoms of schizophrenia by altering the accumulation of specific types of GABA receptors. These animals show both behavioral and brain activity changes that are reminiscent of patients with schizophrenia. To whom correspondence should be addressed. E-mail: stephen.moss@tufts.edu.
This article contains supporting information online at www.pnas.org/lookup/suppl/doi:10. 1073/pnas.1308706110/-/DCSupplemental. unaltered (P < 0.01; SI Appendix, Fig. S1 D and E). Collectively, these results are consistent with CD4DN1 disrupting the accumulation of GABA A Rs at inhibitory synapses. The reduced decay times are suggestive of the selective loss of GABA A R α2 subunits at inhibitory synapses and their possible replacement by α1 subunits (10, 11) .
To evaluate the effects of DN1 on the number and size of inhibitory synapses in the intact brain we created adeno-associated viruses (AAV; 2.9 serotype) expressing DN1 (AAV-DN1) or GFP (AAV-GFP). Cultured cortical neurons were infected at day 2 in vitro (Div) to examine the ability of these viruses to disrupt GABA A R clustering (SI Appendix, Fig. S2 ; data summarized in SI Appendix, Table S2 ). At 14-Div (12 d postinfection) the number of α2 subunit clusters was significantly reduced by AAV-DN1 compared with AAV-GFP (P < 0.01; SI Appendix, Fig. S2 ).
AAV-DN1 Selectively Modifies the Clustering of α2 Subunit-Containing GABA A Rs at Perisomatic Synapses in the Cortex. To examine the effects of the respective viruses on GABA A R clustering in vivo we used stereotaxic injection to infect the frontal cortex of the mouse using two sites bilaterally [ Fig. 1B ; anteroposterior 2.5, 1.0; mediolateral ±1.0; dorsoventral 0.5 (12) ]. On average, injections spanned from the anterior frontal cortex with some cells spreading posterior into the premotor and motor areas (SI Appendix, Fig. S3 ). The highest levels of expression were achieved in cells of the frontal association, cingulate and prelimbic cortical areas. The effects of the respective viruses on α2 subunit clustering was then determined using immunohistochemistry ( Fig. 1 C-F ; data summarized in SI Appendix, Table S3 ).
Expressing cells were identified using an anti-GFP antibody, and masks were drawn based on GFP staining. Quantification of perisomatic puncta revealed that AAV-DN1 significantly reduced the number of GABA A R α2-containing clusters (P < 0.001; Fig Fig. S4C ), suggesting that AAV-DN1 selectively modifies clustering rather than simply decreasing expression levels of the α2 subunit.
Next we examined effects of the AAV-DN1 on α2-containing clusters on the axon-initial segment, which was identified using a Pan-sodium channel antibody (Pan-Na 2+ channel; Fig. 1 E and F). In contrast to the effect on perisomatic synapses, we did not detect any difference in the number, size, or intensity of GABA A R α2 clusters on the AIS comparing neurons infected with AAV-DN1 and AAV-GFP (SI Appendix, Fig. S4 D-F) . We also noted that there was an absence of GFP staining along the axon-initial segment in both AAV-GFP and AAV-DN1-expressing cells, suggesting that the gene products of the viral constructs may not be capable of accessing this highly specialized domain of neurons. No changes were observed in the number of GABA A R α2 away from the perisomatic region in dendritic or neuropil areas (SI Appendix, Fig. S4G ).
To examine the specificity of AAV-DN1 we examined effects on the clustering of GABA A Rs containing α1 subunits ( Fig. 2 A and B; data summarized in SI Appendix, Table S4 ). This revealed a significant increase in the number of perisomatic clusters containing α1 subunits in AAV-DN1-infected neurons (P = 0.002; SI Appendix, Fig. S5A ), whereas their size was unaffected (P = 0.556; SI Appendix, Fig. S5B) ; however, there was a significant increase in GABA A R α1 average integrated intensity (P = 0.036; SI Appendix, Fig. S5C ). Thus, in parallel with decreasing α2 subunit clustering, AAV-DN1 increases the number of α1 subunitcontaining clusters.
We also examined the effects on presynaptic GABAergic specializations by measuring GAT-1 immunorecativity in periosmatic neuronal domains ( Fig. 2 C and D ; data summarized in SI Appendix, Table S4 ). We found a significant decrease in the number of GAT-1-positive puncta in neurons expressing AAV-DN1 (P = 0.047; SI Appendix, Fig. S5D ). Likewise, cluster size was also reduced (P = 0.045; SI Appendix, Fig. S5E ), and we also observed a decrease in the average integrated intensity of GAT-1 immunoreactivity compared with AAV-GFP (P = 0.035; SI Appendix, Fig. S5F ), suggesting a down-regulation of GAT-1 expression in response to altered α2 localization.
Prepulse Inhibition Is Impaired in Mice Expressing AAV-DN1. To assess the impact of the reductions in α2 subunit-containing synapses on behavioral phenotypes relevant to schizophrenia, we began by testing prepulse inhibition (PPI). Deficits in PPI have been strongly linked with schizophrenia, and PPI is a valuable tool for testing the validity of animal models and screening of potential therapeutics (13) . Before testing PPI, we established that the baseline startle response to a 120-dB pulse did not differ between AAV-GFP (1.24 ± 0.20) or AAV-DN1 (1.41 ± 0.14; P = 0.134) expressing mice (Fig. 3A) . For PPI, we compared AAV-GFP and AAV-DN1-injected mice over a range of prepulse intensity levels (70-88 dB) and found that mice expressing AAV-DN1 displayed deficits in relative inhibition (significant effect of virus type; P = 0.007), particularly at the lower prepulse intensity levels (Fig. 3B) . We went on to test the pharmacological validity of this model by pretreatment of groups of mice with either the atypical antipsychotic clozapine (3 mg/kg), the classical antipsychotic haloperidol (1 mg/kg), or a vehicle control 30 min before PPI testing. We found that both clozapine (P = 0.036) and haloperidol (P = 0.016) treatment improved relative inhibition in AAV-DN1 mice but did not result in significant change in AAV-GFP mice (P = 0.517; P = 0.638; SI Appendix, Fig. S6 A and B) . Although we observed striking improvements in PPI following antipsychotic treatment in mice expressing AAV-DN1, the effect of antipsychotics on PPI deficits in human subjects with schizophrenia is variable and has been suggested to be compoundspecific (14, 15) .
Mice Expressing AAV-DN1 Exhibit Impairments in Working Memory.
We next set out to examine phenotype categories relevant to the positive, negative, and cognitive symptoms observed in schizophrenia. Hyperlocomotion induced by noncompetitive NMDA receptor antagonists is commonly used as an animal model of positive symptoms (16) . We first exposed AAV-expressing mice to the open field and allowed them to habituate; no differences were observed in basal open field activity between AAV-GFP (6,832 ± 395 cm) and AAV-DN1 (7,099 ± 451 cm; P = 0.663) expressing mice (SI Appendix, Fig. S7 A and B) . After habituation, mice were removed from the open field, injected with either MK-801 (0.20 mg/kg) or saline, and returned to the open field for an additional 60 min. Mice expressing AAV-DN1 did not differ from AAV-GFP controls in their hyperlocomotor response to MK-801 (21,472 ± 3,370 cm vs. 17,340 ± 2,356 cm; P = 0.339; SI Appendix, Fig. S7 C and D) .
In a separate cohort of matched AAV-expressing mice we also assessed behaviors possibly relevant to negative symptoms including nest building (17-21) and reciprocal social interaction (22, 23) . AAV-expressing mice did not differ in either nest score (3.58 ± 0.42 vs. 3.42 ± 0.43; P = 0.811) or weight of unused nestlet (1.01 ± 0.29 g vs. 1.13 ± 0.31 g; P = 0.837; SI Appendix, Fig. S7E ). We also measured social interaction of AAVexpressing mice in a reciprocal social interaction paradigm. AAV-expressing test mice are simultaneously placed into a neutral home cage with a novel, age-matched target male (Friend Virus B (FVB) strain) and allowed to interact freely for 5 min (22) . AAV-DN1-expressing mice did not differ in either the total time spent interacting (119.88 ± 3.13 s vs. 123.38 ± 3.42 s; P = 0.463) or average length of interaction (7.13 ± 1.20 s vs. 6.63 ± 1.15 s; P = 0.768) with the target mouse (SI Appendix, Fig. S7F ).
To examine cognitive function relevant to schizophrenia, we used spontaneous T-maze alternation as a measure of working memory (24) due to the link between frontal cortex function, working memory, and schizophrenia (25) . AAV-GFP-expressing mice perform on average 73.3 ± 6.7% correct in a series of six discrete trials over 2 days (Fig. 4A) . In contrast, mice expressing AAV-DN1 perform on average 42.4 ± 7.9% correct, a significant impairment compared with AAV-GFP mice (P = 0.010). We also evaluated whether this deficit was responsive to treatment with antipsychotic medication, similar to that observed with PPI. Mice were injected with clozapine (3 mg/kg), haloperidol (1 mg/kg), or vehicle control 30 min before testing. Neither clozapine (33.3 ± 10.2%; P = 0.523) nor haloperidol (30.3 ± 9.8%; P = 0.656) improved cognitive performance of AAV-DN1-expressing mice (Fig. 4B) . Collectively, these results suggest that compromising the synaptic accumulation of GABA A Rs containing α2 subunits in mice leads to cognitive deficits. Moreover these deficits are insensitive to typical antipsychotic drugs, as is the case with cognitive symptoms in human patients.
Reduction in γ-Power in Mice Expressing AAV-DN1. It has been established that cognitive processes engage networks of neurons in synchronous rhythmic activity that is controlled by inhibitory interneuron firing (26, 27) . In particular, the γ-frequency range (>25 Hz) has been linked both to cognitive function and the pathophysiology of schizophrenia (3, 28) . To follow up on the PPI and working memory deficits observed in mice expressing AAV-DN1, we conducted electroencephalography (EEG) recordings in awake, freely moving mice expressing either AAV-GFP or AAV-DN1. Recordings were normalized to the average power of the EEG between 0.5 and 80 Hz. Fast-Fourier transform (FFT) analysis highlighted an area of difference in the higher-frequency range (significant effect of virus type; P < 0.001; Fig. 5A ). Specific examination of γ-band activity (representative traces, Fig. 5B ; 30-80 Hz) revealed a significant suppression of power in AAV-DN1-expressing mice (significant effect of virus type; P = 0.008; Fig. 5C ). Average power in the γ-range in AAV-DN1-expressing mice was significantly reduced (0.119 ± 0.0287; P < 0.001) compared with AAV-GFP (0.369 ± 0.0407; Fig. 5D ). Power in the δ (1-4 Hz), θ (5-8 Hz), and α (9-12 Hz) bands was not altered in AAV-DN1-expressing mice (Fig. 5 A and D) . Raw FFT analysis also showed a significant difference between AAV-GFP and AAV-DN1 (SI Appendix, Fig. S8 ).
Discussion
Postmortem studies have correlated changes in cortical GABA A R α2 subunits and GAT-1 with the pathophysiology of schizophrenia, and these changes are hypothesized to underlie the cognitive symptoms (28, 29) . We have directly tested the role that GABA A Rs play in these deficits using a dominant-negative tool (AAV-DN1) to disrupt the clustering of GABA A R α2 subunits. We observed that AAV-DN1 expression results in alterations in GABA A R α2 and GAT-1 clustering and impaired PPI but does not alter animal performance in models of psychosis, nest building, or social interaction. Cognitive deficits in AAV-DN1-expressing mice were also seen using the T-maze, which correlated with a reduction in the power of γ-oscillatory activity. Thus, these results strongly suggest that GABAergic control of cortical activity is an important determinant of cognition.
There are important distinctions between the effects of the dominant-negative agents used here in mouse brain data and data from postmortem studies of human cortex. It is well established in mice that α2-containing synapses are enriched on the axon-initial segment and perisomatic region opposed to chandelier cell and cholecystokinin (CCK)-basket cell contacts, respectively, whereas perisomatic α1-containing synapses are opposed to fast-spiking parvalbumin (PV)-positive basket cells. In tissue sections from human subjects with schizophrenia a variety of GABA-related deficits have been observed. Specifically, studies of frontal cortex tissue have shown reductions in GAT-1 (30) and GABA A R α1 mRNA expression and reduced density of ankyrin-G immunoreactivty (31) along with an increase in α2 expression (32) along axon-initial segments, as well as deficits in transcripts encoding CCK (33) and cannabinoid 1 receptor (34) .
We have shown a selective reduction of GAT-1 and alterations in the localization of GABA A R α2 clusters, accompanied by an increase in GABA A R α1 on the perisomatic region. This preferential inhibitory effect of AAV-DN1 on α2-containing synapses likely reflects the lower affinity of gephyrin for the α2 subunit compared with α1 and α3 (9) . Alternatively, this may reflect disruption of collybistin binding which shares a common binding site with gephyrin on the α2 subunit (35) . The effects of AAV-DN1 do not precisely mimic those seen in human postmortem tissue; however, in human tissues it remains to be determined if the HRP immunoreactivity corresponds to individual inhibitory synapses and parallel measurements of α1 and α2-positive synapses within individual neuronal compartments measured in these studies.
Axon-initial segment and perisomatic synapses are thought to be important for synchronization of large populations of pyramidal neurons. Kinetic modeling studies suggest any alterations in the kinetics of GABAergic responses will alter the power and frequency of γ-oscillations (36). Functionally, γ-band oscillations in human prefrontal cortex increase proportionally with working memory load (37) , and extracellular GABA increases during completion of working memory tasks and is predictive of γ-band network entrainment (38) . Of particular interest, schizophrenic patients have been shown to have reduced prefrontal γ-oscillations in association with working memory tasks (39) . Here we show that impairment of GABA A R α2-containing perisomatic synapses combined with enhancement of GABA A R α1-containing perisomatic synapses in the frontal cortex results in a significant reduction in γ-power with an associated cognitive deficit. The effects on γ-power may relate to AAV-DN1 effects on GABA A R α2 localization directly or alternatively to the resulting replacement of perisomatic GABA A R α2 with α1 subtypes caused by AAV-DN1 expression. It is accepted that synaptic currents mediated by α2-containing receptors have significantly slower decay than synaptic currents mediated by α1 (10, 11) . Therefore, the replacement of α2 with α1-containing receptors could have important consequences for the efficacy and timing of GABAergic hyperpolarization. These data suggest that modulation of GABA A R function represents a powerful means of regulating cortical activity and mediating cognitive function such as working memory. Thus, potentiating the activity of α2 subunit-containing GABA A Rs may be of benefit in correcting the cognitive deficits seen in schizophrenia. In keeping with this, selective α2/3 allosteric modulators such as MK-0777 have shown some promise in improving working memory and restoring γ-oscillations (40) . However, in a larger randomized clinical trial of MK-0777 in schizophrenic patients, significant improvements in working memory and cognition did not materialize, which may reflect the low efficacy of MK-0777, as it is a relatively weak GABA A R allosteric modulator (41) .
In summary, our data provide evidence that α2 subunitcontaining GABA A Rs are important determinants of working memory and γ-power. In addition mice expressing AAV-DN1 may be useful as a component animal model of pathophysiology relevant to schizophrenia, providing a platform for the screening of potential cognition-improving therapeutics.
Materials and Methods
Additional details of the methods can be found in SI Appendix, Methods.
Housing and Handling of Animals. All procedures were carried out in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals, and were approved by Tufts University and the Institutional Animal Care and Use Committee.
Constructs and Vectors. The constructs used to derive AAV-DN1 have been described previously (8) . To create AAV-DN1 the respective GFP/CD4 fusion protein was cloned into pZac2.1 (http://www.med.upenn.edu/gtp/vectorcore/) and packaged in the AAV 2.9 serotype for neuronal expression.
Electrophysiology. cDNAs were introduced into 8-10 Div cultured neurons, and 48-72 h later mIPSC were measured as described previously (42) .
Immunohistochemistry. Immunohostochemistry was performed as described in ref. 43 .
Behavioral Analysis. PPI testing was conducted according to (44) , the open field apparatus was based on that used in the European Mouse Phenotyping Resource for Standardized Screens (EMPReSS) resource (45), nesting behavior was conducted as described in ref. 17 , reciprocal social interaction paradigm was based on that used in ref. 22 , and spontaneous alternation was based on ref. 46 .
Electroencephalography. EEG and electromyography (EMG) electrodes were implanted under ketamine and xylazine anesthesia. After 5 d of postoperative recovery, EEG activity was measured as detailed in SI Appendix, Methods.
